Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8814950 | 1.00 | SLC6A4 (1.00) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL9325372 | 0.94 | SLC6A4 (0.89) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL9325382 | 0.94 | SLC6A4 (0.89) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8806272 | 0.93 | SLC6A4 (0.86) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8814712 | 0.88 | SLC6A4 (0.78) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8815518 | 0.88 | SLC6A4 (0.78) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL9326522 | 0.87 | SLC6A4 (0.77) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL9326970 | 0.86 | SLC6A4 (0.75) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8814477 | 0.86 | SLC6A4 (0.75) | SLC6A4HTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8807661 | 0.86 | SLC6A4 (0.75) | SLC6A4HTR1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0646112-A4 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS. | ABBOTT LAB (US) | 1997-04-02 | — | — | EP | claimed |
| EP-0646112-A1 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-04-05 | — | — | EP | claimed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | claimed |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | KYOTO UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | KYOTO UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8580832-B2 | Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-12 | — | — | US | disclosed |
| US-8445690-B2 | Aminothiazolones as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-21 | — | — | US | disclosed |
| US-8426604-B2 | Aminothiazolones as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-23 | — | — | US | disclosed |
| US-8399681-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20070213370-A1 | 5-HTP Combination Therapy | H. LUNDBECK A/S (DK) | 2007-09-13 | — | — | US | disclosed |
| US-20070213370-A1 | 5-HTP Combination Therapy | H. LUNDBECK A/S (DK) | 2007-09-13 | — | — | US | disclosed |
| US-20070117844-A1 | 5-HTP combination therapy | H. LUNDBECK A/S (DK) | 2007-05-24 | — | — | US | disclosed |
| US-20070117844-A1 | 5-HTP combination therapy | H. LUNDBECK A/S (DK) | 2007-05-24 | — | — | US | disclosed |
| US-20070066601-A1 | Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066601-A1 | Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070042014-A1 | Combination of a serotonin reuptake inhibitor and loxapine | H. LUNDBECK A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070042014-A1 | Combination of a serotonin reuptake inhibitor and loxapine | H. LUNDBECK A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117844-A1 | 5-HTP combination therapy | TPH1, HTR1A, HTR4 | SLC6A4 17/4885HTR1A 2/4885ADRA2A 98/4885 |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | ADRA2A, ADRB2, ADRA2B | SLC6A4 1339/4885HTR1A 96/4885ADRA2A 1/4885 |
| US-20070213370-A1 | 5-HTP Combination Therapy | TPH1, HTR1A, HTR4 | SLC6A4 17/4885HTR1A 2/4885ADRA2A 98/4885 |
| US-20070066601-A1 | Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | HTR3B, HTR2C, HTR4 | SLC6A4 40/4885HTR1A 8/4885ADRA2A 57/4885 |
| US-20070042014-A1 | Combination of a serotonin reuptake inhibitor and loxapine | HTR2C, HTR3A, HTR3B | SLC6A4 9/4885HTR1A 7/4885ADRA2A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.